울혈성 심부전 치료 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 지역별, 부문별 예측(2025-2030년)

Congestive Heart Failure Treatment Devices Market Growth & Trends:

The global congestive heart failure treatment devices market size is expected to reach USD 8.2 billion in 2030 and is projected to grow at a CAGR of 6.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising burden of CVDs is one of the prime factors responsible for lucrative growth of this vertical. Sedentary lifestyles, mental stress, and junk food consumption tendencies are the key factors responsible for development of CVDs.

Favorable reimbursement policies, such as the U.S. Medicare system, are observed to be a prime growth factor for this industry. Companies now provide new product platforms, which have reimbursement coverage that benefit the patient. The reimbursement can be availed for devices, such as Ventricular Assist Devices (VADs), Implantable Cardiovascular Defibrillators (ICDs), and pacemakers, which are used to treat CHF.

The industry participants are more focused on developing high-utility products, which can deliver personalized care. These advancements are improving the accuracy and provide additional capabilities to enhance the workflow and reduce the incidence of errors.

Congestive Heart Failure Treatment Devices Market Report Highlights:

• The market by product is segmented into VADs, Counter Pulsation Devices, ICDs, pacemakers, and cardiac resynchronization devices. The ICD segment consisting of two types, transvenous and subcutaneous, held a lucrative share in 2024, which was followed by the pacemaker's segment. This can be attributed to the fact that defibrillators and pacemakers form the primary line of treatment administered for heart failure.
• On the other hand, the VAD segment is anticipated to grow at a significant rate over the forecast period due to reimbursement coverage and technological advancements in VADs.
• The VAD based on the site of implantation are categorized into Left Ventricular Assist Devices (LVAD) and Right Ventricular Assist Devices (RVAD). When the LVAD and RVAD are implanted together they are termed Biventricular Assist Devices (BIVAD).
• North America congestive heart failure treatment devices market dominated the global market with a 45.6% share in 2024, this can be attributed to the presence of a large population base suffering from CVDs coupled with a significant geriatric population base.
• The market participants are actively involved in the improvement of the current product portfolio, in order to sustain their market position. Additionally, drug development and their market entry in the untapped nations are expected to propel market growth.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Regional scope
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Congestive Heart Failure Treatment Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cardiovascular diseases
    • 3.2.1.2. Technological advancements in heart failure treatment
    • 3.2.1.3. Growing awareness and early detection of heart failure
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of devices
    • 3.2.2.2. Complications and risks associated with device implantation
• 3.3. Congestive Heart Failure Treatment Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Congestive Heart Failure Treatment Devices Market: Product Estimates & Trend Analysis

• 4.1. Global Congestive Heart Failure Treatment Devices Market: Product Dashboard
• 4.2. Global Congestive Heart Failure Treatment Devices Market: Product Movement Analysis
• 4.3. Global Congestive Heart Failure Treatment Devices Market by Product, Revenue
• 4.4. Ventricular Assist Devices
  • 4.4.1. Ventricular assist devices market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. LVAD
    • 4.4.2.1. LVAD market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. RVAD
    • 4.4.3.1. RVAD market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. BiVAD
    • 4.4.4.1. BiVAD market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Counter Pulsation Devices
  • 4.5.1. Counter pulsation devices market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Implantable Cardioverter Defibrillators
  • 4.6.1. Implantable cardioverter defibrillators market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.2. Transvenous ICDs
    • 4.6.2.1. Transvenous ICDs market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.3. Subcutaneous ICDs
    • 4.6.3.1. Subcutaneous ICDs market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Pacemakers
  • 4.7.1. Pacemakers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.2. Implantable
    • 4.7.2.1. Implantable market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.3. External
    • 4.7.3.1. External market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Cardiac Resynchronization Therapy
  • 4.8.1. Cardiac resynchronization therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.2. Cardiac resynchronization therapy-defibrillators (CRT-D)
    • 4.8.2.1. Cardiac resynchronization therapy-defibrillators (CRT-D) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.3. Cardiac Resynchronization Therapy-Pacemakers (CRT-P)
    • 4.8.3.1. Cardiac Resynchronization Therapy-Pacemakers (CRT-P) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Congestive Heart Failure Treatment Devices Market: Regional Estimates & Trend Analysis by Product

• 5.1. Regional Dashboard
• 5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.3. North America
  • 5.3.1. U.S.
    • 5.3.1.1. Key country dynamics
    • 5.3.1.2. Regulatory framework/ reimbursement structure
    • 5.3.1.3. Competitive scenario
    • 5.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.2. Canada
    • 5.3.2.1. Key country dynamics
    • 5.3.2.2. Regulatory framework/ reimbursement structure
    • 5.3.2.3. Competitive scenario
    • 5.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.3. Mexico
    • 5.3.3.1. Key country dynamics
    • 5.3.3.2. Regulatory framework/ reimbursement structure
    • 5.3.3.3. Competitive scenario
    • 5.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Europe
  • 5.4.1. UK
    • 5.4.1.1. Key country dynamics
    • 5.4.1.2. Regulatory framework/ reimbursement structure
    • 5.4.1.3. Competitive scenario
    • 5.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Germany
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework/ reimbursement structure
    • 5.4.2.3. Competitive scenario
    • 5.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. France
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework/ reimbursement structure
    • 5.4.3.3. Competitive scenario
    • 5.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Italy
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Regulatory framework/ reimbursement structure
    • 5.4.4.3. Competitive scenario
    • 5.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Spain
    • 5.4.5.1. Key country dynamics
    • 5.4.5.2. Regulatory framework/ reimbursement structure
    • 5.4.5.3. Competitive scenario
    • 5.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Norway
    • 5.4.6.1. Key country dynamics
    • 5.4.6.2. Regulatory framework/ reimbursement structure
    • 5.4.6.3. Competitive scenario
    • 5.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.7. Sweden
    • 5.4.7.1. Key country dynamics
    • 5.4.7.2. Regulatory framework/ reimbursement structure
    • 5.4.7.3. Competitive scenario
    • 5.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.8. Denmark
    • 5.4.8.1. Key country dynamics
    • 5.4.8.2. Regulatory framework/ reimbursement structure
    • 5.4.8.3. Competitive scenario
    • 5.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Japan
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework/ reimbursement structure
    • 5.5.1.3. Competitive scenario
    • 5.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. China
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. India
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework/ reimbursement structure
    • 5.5.3.3. Competitive scenario
    • 5.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.4. Australia
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Regulatory framework/ reimbursement structure
    • 5.5.4.3. Competitive scenario
    • 5.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.5. South Korea
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Regulatory framework/ reimbursement structure
    • 5.5.5.3. Competitive scenario
    • 5.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.6. Thailand
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Regulatory framework/ reimbursement structure
    • 5.5.6.3. Competitive scenario
    • 5.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Latin America
  • 5.6.1. Brazil
    • 5.6.1.1. Key country dynamics
    • 5.6.1.2. Regulatory framework/ reimbursement structure
    • 5.6.1.3. Competitive scenario
    • 5.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Argentina
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework/ reimbursement structure
    • 5.6.2.3. Competitive scenario
    • 5.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. MEA
  • 5.7.1. South Africa
    • 5.7.1.1. Key country dynamics
    • 5.7.1.2. Regulatory framework/ reimbursement structure
    • 5.7.1.3. Competitive scenario
    • 5.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Saudi Arabia
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework/ reimbursement structure
    • 5.7.2.3. Competitive scenario
    • 5.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.3. UAE
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Regulatory framework/ reimbursement structure
    • 5.7.3.3. Competitive scenario
    • 5.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.4. Kuwait
    • 5.7.4.1. Key country dynamics
    • 5.7.4.2. Regulatory framework/ reimbursement structure
    • 5.7.4.3. Competitive scenario
    • 5.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company/Competition Categorization
• 6.2. Vendor Landscape
  • 6.2.1. Key company market share analysis, 2024
  • 6.2.2. Jarvik Heart Inc.
    • 6.2.2.1. Company overview
    • 6.2.2.2. Financial performance
    • 6.2.2.3. Product benchmarking
    • 6.2.2.4. Strategic initiatives
  • 6.2.3. ReliantHeart, Inc.
    • 6.2.3.1. Company overview
    • 6.2.3.2. Financial performance
    • 6.2.3.3. Product benchmarking
    • 6.2.3.4. Strategic initiatives
  • 6.2.4. Biotronik SE & Co. KG
    • 6.2.4.1. Company overview
    • 6.2.4.2. Financial performance
    • 6.2.4.3. Product benchmarking
    • 6.2.4.4. Strategic initiatives
  • 6.2.5. Berlin Heart GmbH
    • 6.2.5.1. Company overview
    • 6.2.5.2. Financial performance
    • 6.2.5.3. Product benchmarking
    • 6.2.5.4. Strategic initiatives
  • 6.2.6. Abbott
    • 6.2.6.1. Company overview
    • 6.2.6.2. Financial performance
    • 6.2.6.3. Product benchmarking
    • 6.2.6.4. Strategic initiatives
  • 6.2.7. Medtronic
    • 6.2.7.1. Company overview
    • 6.2.7.2. Financial performance
    • 6.2.7.3. Product benchmarking
    • 6.2.7.4. Strategic initiatives
  • 6.2.8. Boston Scientific Corporation
    • 6.2.8.1. Company overview
    • 6.2.8.2. Financial performance
    • 6.2.8.3. Product benchmarking
    • 6.2.8.4. Strategic initiatives
  • 6.2.9. Teleflex, Inc.
    • 6.2.9.1. Company overview
    • 6.2.9.2. Financial performance
    • 6.2.9.3. Product benchmarking
    • 6.2.9.4. Strategic initiatives